Skip to main content
. Author manuscript; available in PMC: 2012 May 19.
Published in final edited form as: Oncogene. 2011 Sep 26;31(20):2545–2554. doi: 10.1038/onc.2011.433

Table 1.

Kras mutation status in MTB/TOM mouse mammary tumor samples.

Kras mutation status % of tumors with Kras mutations
Tumors regressed to a nonpalpable state(17/43) 6/17 * 35%
Tumors regressed but were still palpable(16/43) 7/16 44%
Tumors were dormant or continued growing (10/43) 8/10 80%
*

One sample not determined